Outlook Therapeutics, Inc. — Form 10-Q
Filed August 18, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Robert C. Jahr (CEO) and Lawrence A. Kenyon (CFO) certified the Q2 2026 10-Q filed August 18, 2026. Both officers attest that financial statements fairly present the company's condition and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, deficiencies, or fraud disclosures are mentioned.
Why this rating
Routine executive certifications required by SOX. No red flags disclosed; standard filing formality. Immaterial unless content of underlying 10-Q shows material issues.
See more from August 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.